secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2025-12-23T23:59:59+00:00
Accession:  0001628280-25-058791
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Bioworks COO Reshma Shetty transitions role; Jennifer Wipf assumes ops duties
--------------------------------------------------------------------------------

- Dr. Reshma Shetty steps down as COO effective Jan 1, 2026; remains President and Board member.
- She will focus on expanding autonomous lab for cell engineering service offerings.
- CEO Dr. Jason Kelly assumes principal operating officer oversight duties.
- Jennifer Wipf (ex-CCO/GM) takes on day-to-day operations, reporting to Kelly.
- Wipf brings vaccine and plant management experience from over a decade at Merck.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000162828025058791/0001628280-25-058791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000162828025058791/dna-20251218.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-058791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer